Sameer Desai Vice President, Corporate Development & Investor Relations TTM Technologies, Inc. +1 714 327 3050 sameer.desai@ttmtech.com Technical Inquiries Mark Bowyer Director, Business Development, RF&S BU TTM Technologies, Inc. +1 315 278 5420 mark.bowyer@ttm.com 50Ω to 100Ω broadband balanced to unbalanced transformers: Our new ultra-small broadband transformers XMB0465Z1-50100G and XMB0220K1-50100G are designed to convert single-ended signals to differential ports with an exceptional common mode reject ...

"Our MCM business in the U.S. continues to deliver very strong results. Empowered by the ongoing favorable supply environment, MCM portfolio purchases in the first quarter were a record $316 million, up 34% compared to the year ago quarter, at very attractive returns. MCM also delivered record collections of $454 million in the first quarter, up 23% compared to Q1 a year ago, driven by superior execution." "Our Cabot business in Europe delivered a solid first quarter. Portfolio purchases of $51 million were ...

Headlines BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC) ("Cerence AI"), a global leader pioneering conversational AI-powered user experiences, today reported its second quarter fiscal year 2025 results for the quarter ended March 31, 2025. Results Summary (in millions, except per share data) | | | | Three Months Ended | | | | Six Months Ended | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | March 31, | | | | March 31, | | | | 2025 | | | 2024 | | 2025 | | ...

ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025. Key Quarterly Highlights "The exceptional clinical value delivered by our Light Adjustable Lens continues to drive significant enthusiasm among cataract surgeons," said Ron Kurtz, Chief Executive Officer and President o ...

— Delivered Revenue Growth of 4%, Net Income Growth of 5%, and EPS Growth of 9% — KANSAS CITY, Mo., May 07, 2025 (GLOBE NEWSWIRE) -- H&R Block, Inc. (NYSE: HRB) (the "Company") today released financial results for its fiscal 2025 third quarter ended March 31, 2025. — Improved Volume and Market Share Trends in Assisted Channel Through April 30 — "Today we are reaffirming our FY25 outlook," said Jeff Jones, president and chief executive officer. "Our transformation continues to gather momentum and deliver res ...

Core Viewpoint - Aardvark Therapeutics, Inc. is actively engaging in presenting its clinical developments and strategies at various conferences in May 2025, highlighting its focus on novel therapeutics for metabolic diseases [1][4]. Company Overview - Aardvark Therapeutics is a clinical-stage biopharmaceutical company that develops small-molecule therapeutics aimed at suppressing hunger, particularly for conditions like Prader-Willi Syndrome (PWS) and other metabolic diseases [2]. - The lead compound, ARD-101, is currently in Phase 3 clinical development for treating hyperphagia associated with PWS and is also being studied for hypothalamic obesity [2]. - Aardvark is developing ARD-201, a combination of ARD-101 and a DPP-4 inhibitor, to address limitations of existing GLP-1 therapies for obesity and related conditions [2]. Upcoming Presentations - Aardvark will present at the following conferences: - Bank of America Global Healthcare Conference on May 15, 2025, at 12:35 p.m. ET [4]. - H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 3:30 p.m. ET [4]. - RBC Capital Markets Global Healthcare Conference on May 21, 2025, at 2:35 p.m. ET [4]. - Live webcasts of these presentations will be available on the company's website, with archived recordings accessible for approximately one month post-presentation [1].

- Revenues up 10% to $292.6 Million with Gross Billings up 9% to $2.09 Billion - VANCOUVER, Wash., May 07, 2025 (GLOBE NEWSWIRE) -- Barrett Business Services, Inc. ("BBSI" or the "Company") (NASDAQ: BBSI), a leading provider of business management solutions, reported financial results for the first quarter ended March 31, 2025. All share and per share amounts presented herein have been retroactively adjusted to reflect the impact of the four-for-one stock split that was distributed in the form of a stock di ...

BROOMFIELD, Colo., May 07, 2025 (GLOBE NEWSWIRE) -- Noodles & Company (Nasdaq: NDLS) today announced financial results for its first quarter ended April 1, 2025. Key highlights for the first quarter of 2025 versus the first quarter of 2024 include: Restaurant contribution margin and adjusted EBITDA are non-GAAP measures. Reconciliations of operating income (loss) to restaurant contribution margin and net loss to adjusted EBITDA are included in the accompanying financial data. See "Non-GAAP Financial Measure ...

GAAP Net Income of $0.2 Million or $0.00 per Share; EBITDAR of $20.6 Million Revenue of $66.6 Million with Total Block Hours of 7,546 MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Global Crossing Airlines Group, Inc. (Cboe CA: JET, Cboe CA: JET.B, OTCQB: JETMF) (the "Company" or "GlobalX"), the Nation's fastest growing charter airline, today announced its financial and operating results for the first quarter ended March 31, 2025. Except as otherwise disclosed, all figures for the three-month period are presented ...

Core Insights - Hudson Technologies, Inc. reported a revenue of $55.3 million for Q1 2025, a decrease of 15% compared to $65.3 million in Q1 2024, primarily due to lower refrigerant prices despite a slight increase in sales volume [9][16] - The gross margin for Q1 2025 was 22%, down from 33% in the same period last year, largely driven by price compression in the refrigerant market [9][16] - The company has a strong balance sheet with $81 million in cash and no debt as of March 31, 2025, and has repurchased $4.5 million of common stock in 2025 [4][8] Financial Performance - Revenues for Q1 2025 were $55.3 million, down 15% from $65.3 million in Q1 2024 [9][16] - Gross profit decreased to $12.1 million in Q1 2025 from $21.4 million in Q1 2024, reflecting the decline in gross margin [9][16] - Operating income fell to $3.1 million in Q1 2025 from $12.8 million in the prior year [9][16] - Net income for Q1 2025 was $2.8 million, or $0.06 per share, compared to $9.6 million, or $0.21 per share, in Q1 2024 [9][16] Market and Strategic Insights - The company anticipates continued growth in its reclamation business due to the phase-down of HFC refrigerants under the AIM Act, which is expected to reduce the supply of virgin HFCs [3] - Several states are implementing requirements for the use of reclaimed refrigerants in municipal buildings, creating additional demand opportunities [3] - Hudson Technologies is focused on responsible refrigerant management and has strengthened its capabilities through the acquisition of USA Refrigerants [2][3] Cash Flow and Capital Allocation - Cash provided by operating activities was $14.2 million in Q1 2025, compared to a cash used of $0.9 million in the same period last year [19] - The company invested $1.4 million in property, plant, and equipment during the quarter [20] - Hudson Technologies continues to pursue a capital allocation strategy that includes organic growth investments, acquisitions, and stock repurchases [4][8]